SET8 modulates prognosis and radiotherapeutic efficacy by regulating radiation-induced migration in lung adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.SET8 promotes lung adenocarcinoma cell migration after radiation therapy via the PTTG1-PI3K-AKT pathway. SET8-related genes may predict radiotherapy success and patient survival.
Area Of Science
- Oncology
- Molecular Biology
- Radiotherapy Research
Background
- Tumor cell migration in lung adenocarcinoma (LUAD) reduces radiotherapy efficacy and worsens prognosis.
- SET8, a methyltransferase, is investigated for its role in LUAD cell migration and response to radiotherapy.
Purpose Of The Study
- To investigate the role of SET8 in radiation-induced migration of LUAD cells.
- To explore the potential of SET8 and its associated genes as prognostic markers for LUAD radiotherapy.
Main Methods
- In vitro assays (CRISPR/Cas9 SET8 knockout, wound healing, transwell migration) assessed SET8's impact on radiation-induced LUAD cell migration.
- Bioinformatics analyses (TCGA data) examined SET8 expression, migration, and prognosis.
- Statistical models (Cox, LASSO regression) and drug sensitivity analysis identified prognostic markers and therapeutic targets.
Main Results
- Ionizing radiation increased LUAD cell migration and altered SET8 expression.
- SET8 mediated radiation-induced migration via the PTTG1-PI3K-AKT pathway.
- SET8 depletion inhibited LUAD cell migration post-irradiation; elevated SET8 correlated with metastasis and poor prognosis.
Conclusions
- SET8 drives radiation-induced LUAD cell migration through the PTTG1-PI3K-AKT pathway.
- SET8 and its associated genes serve as potential biomarkers for predicting LUAD radiotherapy outcomes and patient survival.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.